# Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

> **NCT04194931** · PHASE1 · UNKNOWN · sponsor: **The First Affiliated Hospital of Nanchang University** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Autologous BCMA CAR-T cells and CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT04194931
- **Lead sponsor:** The First Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04194931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04194931, "Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04194931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*